Vaccaro Carlos, Zhou Jinchun, Ober Raimund J, Ward E Sally
Center for Immunology, University of Texas Southwestern Medical Center, 6000 Harry Hines Blvd., Dallas, Texas 75390-9093, USA.
Nat Biotechnol. 2005 Oct;23(10):1283-8. doi: 10.1038/nbt1143. Epub 2005 Sep 25.
We have engineered the Fc region of a human immunoglobulin G (IgG) to generate a mutated antibody that modulates the concentrations of endogenous IgGs in vivo. This has been achieved by targeting the activity of the Fc receptor, FcRn, which serves through its IgG salvage function to maintain and regulate IgG concentrations in the body. We show that an IgG whose Fc region was engineered to bind with higher affinity and reduced pH dependence to FcRn potently inhibits FcRn-IgG interactions and induces a rapid decrease of IgG levels in mice. Such FcRn blockers (or 'Abdegs,' for antibodies that enhance IgG degradation) may have uses in reducing IgG levels in antibody-mediated diseases and in inducing the rapid clearance of IgG-toxin or IgG-drug complexes.
我们对人免疫球蛋白G(IgG)的Fc区域进行了改造,以生成一种能在体内调节内源性IgG浓度的突变抗体。这是通过靶向Fc受体FcRn的活性实现的,FcRn通过其IgG挽救功能来维持和调节体内的IgG浓度。我们发现,一种Fc区域经过改造、能以更高亲和力且降低pH依赖性与FcRn结合的IgG,可有效抑制FcRn-IgG相互作用,并导致小鼠体内IgG水平迅速下降。这类FcRn阻断剂(或“Abdegs”,即增强IgG降解的抗体)可能在降低抗体介导疾病中的IgG水平以及诱导IgG-毒素或IgG-药物复合物的快速清除方面具有应用价值。